
Global Blood Therapeutics (NASDAQ:GBT) brought in sales totaling $56.10 million during Q4 according to data provided by Benzinga Pro. However, earnings decreased 23.37%, resulting in a loss of $87.58 million. In Q3, Global Blood Therapeutics brought in $52.05 million in sales but lost $70.99 million in earnings.